Novel Biologics: Designed by evolution. Discovered by AI.
AI-derived novel biologics
Belfast-based AMPLY raises £900k to tackle drug-resistant pathogens with AI
Belfast-based startup AMPLY has raised £900,000 in a joint equity and grant funding round to develop new products that tackle global disease threats from multi-drug
Targeting multi-drug resistant bacteria with novel Cannabis compounds recovered directly from deep mining the genome
Targeting multi-drug resistant bacteria with novel Cannabis compounds recovered directly from deep mining the genome With bioclinical partners AMPLY located a series of novel antimicrobial
Recovering novel small proteins from the skin and liver transcriptomes of Peruvian tree frogs
AMPLY can process publicly available digital biological data. But it can also process unique data collected at remote sites. Members of the AMPLY team travelled
biomining biological big data for novel biologics
Reinventing Traditional Drug Discovery
The amplyfolio ai platform
Bringing financial style stock selection to drug discovery
The digital biome offers huge potential for recovering proteinaceous compounds shaped by tens of thousands of years of evolution. But finding good compounds that can be synthesised artificially and work in the lab is a challenge. AMPLYfolio AI, our award-winning software platform, meets this challenge through combining bioinformatic techniques and approaches from other industries (such as asset management and predictive marketing) alongside a unique human decision-making dashboard which focuses on novelty and IP protectability.